NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-08-31
Reading DHR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Increase adjusted EPS to $8.35-$8.55 in 2026: EPS $8.45-$8.60 vs $8.35 target.
Danaher grows revenue 3% to 6% yearly. Profit per share is rising, with guidance at $8.45 for 2026. The company buys back shares, showing strong capital use. Its quality score improved significantly.
Revenue growth lags the 3% to 6% target. Profit growth may slow given soft guidance. Capital obligations and volatile management raise risks.
The price is about 2% below our fair value near $197. Analysts expect 9% revenue growth, which is above management's 3% to 6% target. Our fair value is 14% below the Street median, reflecting more cautious growth assumptions.
Breaks if: Adjusted EPS guidance falls below $8.35 for FY26
Danaher has increased its full year adjusted diluted EPS guidance to $8.35 to $8.55.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on steady revenue growth and earnings improvement. The current thesis state is intact, supported by recent strong financial results and management's guidance.
The market appears to have priced in a premium compared to peers, reflecting a justified valuation despite being considered expensive. Expectations are closely aligned with management's guidance, indicating that any negative surprises could impact sentiment.
Fundamentals are likely to remain stable, with management on track to achieve its revenue growth and earnings targets for 2026. However, there is a moderate risk due to the company's recent history of misses and the potential for guidance cuts.
The long-term thesis hinges on external factors such as the performance of the broader healthcare sector and key competitors. Additionally, management's ability to maintain guidance and execute on their share buyback program will be crucial.
The most important moves since the prior daily snapshot.
The recent news cuts both ways. It is challenged by grow core revenue 3% to 6%. It is supported by the latest earnings beat.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: No share buyback activity announced or executed in next 12 months
Breaks if: YoY revenue growth falls below 3% in FY26
Overall, Danaher Corporation has a solid foundation but must navigate potential risks in the near term. Not investment advice.
